3-[[Di(propan-2-yl)amino]-hexadecoxyphosphanyl]oxypropanenitrile | 141186-19-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-[[Di(propan-2-yl)amino]-hexadecoxyphosphanyl]oxypropanenitrile
• CAS: 141186-19-8
• 化学式: C₂₅H₅₁N₂O₂P
• 分子量: 442.666
• InChiKey: IELIZKBPHPRJBO-UHFFFAOYSA-N

物化性质

• 沸点：
  475.0±28.0 °C(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  9.3
• 重原子数：
  30
• 可旋转键数：
  22
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  45.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-[[Di(propan-2-yl)amino]-hexadecoxyphosphanyl]oxypropanenitrile 在 四氮唑 、 水 、 碘 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 生成 3'-deoxy-2',3'-didehydrothymidine 5'-(2-cyanoethyl hexadecyl phosphate)
  参考文献：
  名称：

  Synthesis and anti-HIV evaluation of D4T and D4T 5'-monophosphate prodrugs

  摘要：

  Several 5-monophosphate D4T derivatives and their analogues were synthesized as potential lipophilic prodrugs of D4T. Cholesteryl D4T phosphate diester and bis-5'-D4T phosphate inhibited HIV replication in CEM-Cl13 cells more efficiently than D4T itself as measured by the inhibition of cytopathic effect based on MTT assay or reverse transcriptase activity. The two compounds were devoid of toxicity on CEM-Cl13 cells at doses equal to 50 and 100 muM, respectively, which brought the selectivity index into the same range as AZT.

  DOI：

  10.1021/jm00059a006
• 作为产物：
  描述：

  1-十六烷醇 、 2-氰乙基N,N-二异丙基氯亚磷酰胺 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.17h， 生成 3-[[Di(propan-2-yl)amino]-hexadecoxyphosphanyl]oxypropanenitrile
  参考文献：
  名称：

  [EN] PHOSPHATE ESTERS OF GYRASE AND TOPOISOMERASE INHIBITORS
  [FR] ESTERS PHOSPHORIQUES D'INHIBITEURS DE GYRASES ET DE TOPOISOMÉRASES

  摘要：

  本发明涉及抑制细菌旋转酶和/或拓扑异构酶IV的化合物的磷酸酯以及其药物组成物。这些磷酸酯对治疗细菌感染具有用途。

  公开号：

  WO2012177707A1

文献信息

• ADJUVANT IN THE FORM OF A LIPID-MODIFIED NUCLEIC ACID
  申请人：Hoerr Ingmar

  公开号：US20070280929A1

  公开（公告）日：2007-12-06

  The present invention relates to an immune-stimulating adjuvant in the form of a lipid-modified nucleic acid, optionally in combination with further adjuvants. The invention relates further to a pharmaceutical composition and to a vaccine, each containing an immune-stimulating adjuvant according to the invention, at least one active ingredient and optionally a pharmaceutically acceptable carrier and/or further auxiliary substances and additives and/or further adjuvants. The present invention relates likewise to the use of the pharmaceutical composition according to the invention and of the vaccine according to the invention for the treatment of infectious diseases or cancer diseases. Likewise, the present invention includes the use of the immune-stimulating adjuvant according to the invention in the preparation of a pharmaceutical composition for the treatment of cancer diseases or infectious diseases.

  本发明涉及一种免疫刺激佐剂，其形式为脂质修饰的核酸，可选地与其他佐剂结合。该发明还涉及一种含有根据本发明的免疫刺激佐剂、至少一种活性成分以及可选的药用载体和/或其他辅助物质和添加剂和/或其他佐剂的药物组合物和疫苗。本发明还涉及根据本发明的药物组合物和疫苗用于治疗传染病或癌症的用途。同样，本发明包括根据本发明的免疫刺激佐剂用于制备用于治疗癌症或传染病的药物组合物的用途。
• NUCLEIC ACID OF FORMULA (I): GlXmGn, OR (II): ClXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT
  申请人：CureVac AG

  公开号：US20200016264A1

  公开（公告）日：2020-01-16

  The present invention relates to a nucleic acid of the general formula (I): G l X m G n , or (II): C l X m C n , which may be modified by a lipid. The nucleic acid of the invention acts as an immune-stimulating agent inducing the innate immune response. The invention relates further to a pharmaceutical composition (in a first embodiment), each containing an immune-stimulating agent according to the invention in combination with a pharmaceutically active carrier/vehicle (and, optionally, further auxiliary substances, additives and/or further adjuvants). In another embodiment, the inventive nucleic acid is combined with at least one pharmaceutically active component, a pharmaceutically acceptable carrier/vehicle (and, optionally, further auxiliary substances, additives and/or further adjuvants). Accordingly, the present invention is directed to a vaccine, which corresponds to a pharmaceutical composition of the invention (second embodiment), wherein the pharmaceutically active component induces a specific immune response (e.g. an antigen). The present invention relates likewise to the use of a nucleic acid of the invention or a pharmaceutical composition according to the invention for the treatment of infectious diseases, autoimmune diseases, allergies or cancer diseases.

  本发明涉及一般式(I)：G l X m G n 或(II)：C l X m C n的核酸，该核酸可以通过脂质进行修饰。本发明的核酸作为免疫刺激剂，诱导先天免疫应答。本发明还涉及一种药物组合物（在第一实施例中），每种组合物包含本发明的免疫刺激剂与药用活性载体/载体（以及可选的进一步辅助物质、添加剂和/或进一步佐剂）的组合。在另一实施例中，创新的核酸与至少一种药用活性成分、药用可接受的载体/载体（以及可选的进一步辅助物质、添加剂和/或进一步佐剂）结合。因此，本发明涉及一种疫苗，该疫苗对应于本发明的药物组合物（第二实施例），其中药用活性成分诱导特异免疫应答（例如抗原）。本发明同样涉及利用本发明的核酸或药物组合物治疗传染病、自身免疫疾病、过敏或癌症疾病。
• NUCLEIC ACID DERIVATIVE HAVING IMMUNOSTIMULATORY ACTIVITY
  申请人：Shionogi & Co., Ltd.

  公开号：US20180264105A1

  公开（公告）日：2018-09-20

  The purpose of the present invention is to provide double-stranded oligonucleotides comprising the CpG oligonucleotide mentioned below, as a nucleic acid derivative having an immunostimulatory activity. An adjuvant comprising a double-stranded oligonucleotide, wherein a first strand is a CpG oligonucleotide consisting of 8 to 50 nucleotides, a second strand is an oligonucleotide consisting of 8 to 60 nucleotides and comprising a sequence capable of hybridizing with the first strand, and a lipid binds to the second strand through a linker.

  本发明的目的是提供包含如下所述CpG寡核苷酸的双链寡核苷酸，作为一种具有免疫刺激活性的核酸衍生物。 一种包含双链寡核苷酸的佐剂，其中 第一链是由8到50个核苷酸组成的CpG寡核苷酸， 第二链是由8到60个核苷酸组成的寡核苷酸，并且包括 能够与第一链杂交的序列，以及通过连接器与第二链结合的脂质。
• Polypeptide Protracting Tags
  申请人：Conde Frieboes Kilian Waldemar

  公开号：US20100029903A1

  公开（公告）日：2010-02-04

  The invention provides novel compounds comprising a protracting tag linked to therapeutically active compounds.

  该发明提供了一种新型化合物，其中包括一个与治疗活性化合物连接的延长标签。
• PHOSPHATE ESTERS OF GYRASE AND TOPOISOMERASE INHIBITORS
  申请人：Bennani Youssef Laafiret

  公开号：US20130157979A1

  公开（公告）日：2013-06-20

  The present invention relates to phosphate esters of compounds that inhibit bacterial gyrase and/or Topoisomerase IV and pharmaceutical compositions thereof. These phosphate esters are useful for treating bacterial infections.

  本发明涉及抑制细菌DNA旋转酶和/或拓扑异构酶IV的化合物的磷酸酯及其制药组合物。这些磷酸酯对治疗细菌感染有用。